Loading clinical trials...
Loading clinical trials...
Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Conditions
Interventions
Cetuximab-IRDye800
Locations
1
United States
Stanford University, School of Medicine
Stanford, California, United States
Start Date
November 1, 2015
Primary Completion Date
April 19, 2017
Completion Date
April 19, 2017
Last Updated
June 24, 2019
NCT04585750
NCT07457346
NCT06636188
NCT05526924
NCT07065630
NCT07447050
Lead Sponsor
Eben Rosenthal
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions